A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system

Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial

(2021) Michael B. Atkins et al.   EUROPEAN JOURNAL OF CANCER

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS

(2021) Chenxin Chen et al.   Frontiers in Pharmacology

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database

(2021) Long Meng et al.   Frontiers in Medicine

Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study

(2021) Adam Goldman et al.   Targeted Oncology

Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system

(2021) Chen Chen et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

The efficacy of axitinib as a first‐line treatment for metastatic renal cell carcinoma

(2020) Tomohiro Kameda et al.   Asia-Pacific Journal of Clinical Oncology

A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib

(2020) Ling Peng et al.   Expert Opinion On Drug Safety

Axitinib‐induced scrotal ulcers: a novel cutaneous adverse event

(2020) AA Stefaniak et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Brian I. Rini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessing Fluoroquinolone-associated Aortic Aneurysm and Dissection: Data Mining of the Public Version of the FDA Adverse Event Reporting System

(2019) Long Meng et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment

(2019) Nanna Bæk Møller et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients

(2018) Matthias Totzeck et al.   European Journal of Preventive Cardiology

EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer

(2018) Yasuo Oshima et al.   JAMA Oncology

Epidemiology of Renal Cell Carcinoma

(2018) Umberto Capitanio et al.   EUROPEAN UROLOGY

First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data

(2018) Xinan Sheng et al.   Future Oncology

Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials

(2017) Jing Li et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Hypertension Induced by Tyrosine-Kinase Inhibitors for the Treatment of Renal Cell Carcinoma in Hemodialysis Patients: A Single-Center Experience and Review of the Literature

(2017) Kentaro Nakai et al.   THERAPEUTIC APHERESIS AND DIALYSIS

Axitinib-induced Pneumatosis Intestinalis and Acute Acalculous Cholecystitis in a Patient With Renal Cell Carcinoma

(2017) Tomohiro Kameda et al.   UROLOGY

Axitinib-related osteonecrosis of the jaw

(2017) Vinod Patel et al.   Oral Surgery Oral Medicine Oral Pathology Oral Radiology

Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib

(2015) Naoya Niwa et al.   ACTA ONCOLOGICA

Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

(2015) Brian I. Rini et al.   Clinical Genitourinary Cancer

Big Data and Adverse Drug Reaction Detection

(2015) R Harpaz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Acute myocardial infarction induced by axitinib

(2014) Emre Gurel et al.   Anadolu Kardiyoloji Dergisi-The Anatolian Journal of Cardiology

Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments

(2014) Laura D. Locati et al.   CANCER

Five-Year Survival in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma Treated With Axitinib

(2013) Brian I. Rini et al.   Clinical Genitourinary Cancer

Dysphonia induced by anti-angiogenic compounds

(2013) Erika Saavedra et al.   INVESTIGATIONAL NEW DRUGS

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

(2013) Thomas E Hutson et al.   LANCET ONCOLOGY

Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use

(2011) Ziya Kirkali   BJU INTERNATIONAL

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

(2011) Brian I Rini et al.   LANCET

Targeted Therapies in Metastatic Renal Cell Carcinoma: Overview of the Past Year

(2011) Marine Gross-Goupil et al.   Current Urology Reports

Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker

(2010) Emily S. Robinson et al.   SEMINARS IN NEPHROLOGY

Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma

(2009) J. Edeline et al.   ANNALS OF ONCOLOGY

Dysphonia induced by vascular endothelium growth factor/vascular endothelium growth factor receptor inhibitors

(2009) Dana M. Hartl et al.   INVESTIGATIONAL NEW DRUGS